Cotización Cannassure Therapeutics Ltd TEL AVIV STOCK EXCHANGE
Acciones
CSURE
IL0001110134
Instalaciones y servicios de atención médica
Ventas 2021 | 34,02 124,74 31,57 | Ventas 2022 | 33,78 123,84 31,34 | Capitalización | 4,6 M 16,88 M 4,27 M |
---|---|---|---|---|---|
Resultado Neto 2021 | -16 M -58,66 M -14,85 M | Resultado Neto 2022 | -5 M -18,33 M -4,64 M | VE / Ventas 2021 | 1.291.150 x |
Deuda neta 2021 | 10,39 M 38,09 M 9,64 M | Deuda neta 2022 | 29,96 M 110 M 27,8 M | VE / Ventas 2022 | 1.023.292 x |
P/E ratio 2021 |
-2,03
x | P/E ratio 2022 |
-0,84
x | Empleados | - |
Rendimiento 2021 * |
-
| Rendimiento 2022 |
-
| Flotante | 50,58 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
Ada Bar Kama
CEO | Chief Executive Officer | 53 | 31/03/22 |
Nir Peles
CHM | Chairman | 50 | 04/12/18 |
Daniel Spira
AUD | Comptroller/Controller/Auditor | 69 | 26/06/19 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Shimon Bar-Kama
BRD | Director/Board Member | 71 | 04/12/18 |
Nir Peles
CHM | Chairman | 50 | 04/12/18 |
Varda Kalal
BRD | Director/Board Member | 56 | 14/02/22 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+31,96 % | 271 M | |
+46,91 % | 285 M | |
+68,02 % | 218 M | |
-20,43 % | 164 M | |
-28,57 % | 122 M | |
+106,22 % | 119 M | |
+15,38 % | 101 M | |
+85,62 % | 85,4 M | |
+150,00 % | 75,33 M |